Araştırma Makalesi

Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole's Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture

Cilt: 18 Sayı: 1 30 Haziran 2025
PDF İndir
EN TR

Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole's Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture

Abstract

Cancer is known as a major health problem globally. Breast cancer is the most common malignant tumor and metastasis continues to be the main cause of poor prognosis. Despite recent advances in cancer treatment, the success of metastatic breast cancer treatment is not at the desired level. Among the anticancer drugs discovered in recent years, various benzimidazole derivatives have attracted attention in the development of anticancer agents due to their various biological activities and clinical applications. The aim of this study was to evaluate the antiproliferative activity of synthesized benzimidazole derivative SA-61 in 4T1 breast cancer cell line in comparison with abemaciclib, which is approved by FDA for the treatment of breast cancer. The antiproliferative activity and apoptotic effect of SA-61 were examined using MTT and immunohistochemical methods, respectively. According to MTT results, compound SA-61 showed antiproliferative activity in 4T1 cells in a dose-dependent manner, but this effect was lower than abemaciclib. Although further studies are needed to specifically identify the compounds involved in its anti-cancer activity, our findings suggest that SA-61 inhibits the proliferation of 4T1 cells and its effect is dose dependent.

Keywords

Kaynakça

  1. Choi HS, Ko YS, Jin H, et al. (2022). Mebendazole increases anticancer activity of radiotherapy in radiotherapy-resistant triple-negative breast cancer cells by enhancing natural killer ccell-mediated cytotoxicity. Int J Mol Sci. 7;23(24):15493.
  2. Medeiros B, Allan AL (2019). Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int. J. Mol. Sci. 20:2272.
  3. Pulaski BA, Ostrand-Rosenberg S (2001). Mouse 4T1 breast tumor model. Curr. Protoc Immunol. 39:20.2.1–20.2.16.
  4. Wagenblast E, Soto M, Gutiérrez-Ángel S, et al. (2015). A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 520:358–362.
  5. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13:674–690.
  6. Lee YT, Tan YJ, Oon CE (2023). Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharm Sin B. 13(2):478-497.
  7. Hagar FF, Abbas SH, Atef E, Abdelhamid D, Abdel-Aziz M (2025). Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016-2023). Mol Divers. 29(2):1821-1849.
  8. Liu Y (2021). Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways. Fundam Clin Pharmacol. 35(1):156–64.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Veteriner Bilimleri (Diğer)

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

30 Haziran 2025

Gönderilme Tarihi

26 Mart 2025

Kabul Tarihi

20 Mayıs 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 18 Sayı: 1

Kaynak Göster

APA
Bilici, E., Gülbenli Türkoğlu, B., & Akkoç, S. (2025). Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniversitesi Veteriner Fakültesi Dergisi, 18(1), 33-37. https://doi.org/10.47027/duvetfd.1666352
AMA
1.Bilici E, Gülbenli Türkoğlu B, Akkoç S. Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniv Vet Fak Derg. 2025;18(1):33-37. doi:10.47027/duvetfd.1666352
Chicago
Bilici, Esra, Büşra Gülbenli Türkoğlu, ve Senem Akkoç. 2025. “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”. Dicle Üniversitesi Veteriner Fakültesi Dergisi 18 (1): 33-37. https://doi.org/10.47027/duvetfd.1666352.
EndNote
Bilici E, Gülbenli Türkoğlu B, Akkoç S (01 Haziran 2025) Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniversitesi Veteriner Fakültesi Dergisi 18 1 33–37.
IEEE
[1]E. Bilici, B. Gülbenli Türkoğlu, ve S. Akkoç, “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”, Dicle Üniv Vet Fak Derg, c. 18, sy 1, ss. 33–37, Haz. 2025, doi: 10.47027/duvetfd.1666352.
ISNAD
Bilici, Esra - Gülbenli Türkoğlu, Büşra - Akkoç, Senem. “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”. Dicle Üniversitesi Veteriner Fakültesi Dergisi 18/1 (01 Haziran 2025): 33-37. https://doi.org/10.47027/duvetfd.1666352.
JAMA
1.Bilici E, Gülbenli Türkoğlu B, Akkoç S. Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniv Vet Fak Derg. 2025;18:33–37.
MLA
Bilici, Esra, vd. “Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture”. Dicle Üniversitesi Veteriner Fakültesi Dergisi, c. 18, sy 1, Haziran 2025, ss. 33-37, doi:10.47027/duvetfd.1666352.
Vancouver
1.Esra Bilici, Büşra Gülbenli Türkoğlu, Senem Akkoç. Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole’s Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture. Dicle Üniv Vet Fak Derg. 01 Haziran 2025;18(1):33-7. doi:10.47027/duvetfd.1666352